{"prompt": "['Product: MK-3475', '67', 'Protocol/Amendment No.: 604-09', '26. Etoposide 100 mg/m\u00b2 will be administered as an IV infusion over 30 to 60 minutes (up to 120 minutes to accommodate local standards of care) Q3W on Days 1, 2, and 3.', 'Days 1, 2, and 3 must be consecutive days without interruption. Dose should be recalculated if there is a >10% weight change.', '27. PROs are completed every cycle for Cycles 1 to 9 while the subject is receiving study treatment, then every other cycle up to Cycle 17 (ie, Cycles 11, 13, 15, and 17).', 'PROs will also be obtained at the Treatment Discontinuation visit and 30-day Safety Follow-up visit. If the Treatment Discontinuation visit occurs 30 days from the last', 'dose of study treatment, at the time of the mandatory Safety Follow-up visit, PROs do not need to be repeated. PROs are to be administered by trained site', 'personnel', 'and', 'completed electronically by subjects prior to all other study procedures and receiving results of any tests (including disease status). The PROs', 'should', 'be', 'administered', 'in', 'the following order: EQ-5D-5L, EORTC QLQ-C30, EORTC QLQ-LC13.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '68', 'Protocol/Amendment No.: 604-09', '6.2', 'Second Course Treatment Phase', 'Second course retreatment subjects may receive up to 17 cycles (approximately 1 year) of pembrolizumab therapy. For subjects to be', 'eligible for the Second Course Treatment Phase, it is necessary to fulfill conditions outlined in Section 7.1.5.5', 'and', 'verify', 'progression', 'of disease by BICR.', 'Treatment Phase', 'End of Treatment Phase', 'Follow-up Phase', 'Treatment Cycle/Scheduled', 'Discontinuation Visit\u00b2', '1\u00b9', '2-17', 'Safety Follow up', 'PFS Follow-up4', 'Survival Follow-up 5', 'Time', 'Visit\u00b3', 'Day in cycle', '1', 'NA', 'NA', 'NA', 'NA', 'At Study Drug', '30 Days From', 'Every 6 or 9 weeks', 'Every 8 Weeks 7', 'Scheduling Window (Days):6', '3', '3', 'Discontinuation', 'Last Dose', 'per imaging schedule', '(+3)', '(+7)', '(+7)', 'Administrative Procedures', 'Eligibility Criteria', 'X', 'Prior and Concomitant', 'Medications', 'X', 'X', 'X', 'X', 'X7', 'X7', 'Clinical Procedures / Assessments', 'Review Adverse Events', 'X', 'X', 'X', 'X8', 'X8', 'X8', 'Full Physical Examination', 'X', 'Directed Physical Examination', 'X', 'X', 'X', 'Vital Signs and Weight', 'X', 'X', 'X', 'X', 'ECOG Performance Status', 'X', 'X', 'X', 'X', 'Laboratory Procedures / Assessments: analysis performed by local laboratory', 'CBC with Differential9', 'X', 'X', 'X', 'X', 'PT/INR9', 'X', 'Comprehensive Chemistry Panel9', 'X', 'X', 'X', 'X', 'Urinalysis9,10', 'X', 'X', 'X', 'X', 'Thyroid Function Tests9,11', 'X', 'X', 'X', 'X', 'Pregnancy Test - Serum or', 'Urine12', 'X', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '69', 'Protocol/Amendment No.: 604-09', 'Treatment Phase', 'End of Treatment Phase', 'Follow-up Phase', 'Treatment Cycle/Scheduled', 'Discontinuation Visit\u00b2', '1\u00b9', '2-17', 'Safety Follow up', 'PFS Follow-up4', 'Survival Follow-up 5', 'Time', 'Visit\u00b3', 'Day in cycle', '1', 'NA', 'NA', 'NA', 'NA', 'At Study Drug', '30 Days From', 'Every 6 or 9 weeks', 'Every 8 Weeks 7', 'Scheduling Window (Days):6', '3', '3', 'Discontinuation', 'Last Dose', 'per imaging schedule', '(+3)', '(+7)', '(+7)', 'Efficacy Measurements', 'CT/MRI Imaging of Chest,', 'X', 'X', 'X', 'X', 'X', 'Abdomen, and Pelvis13,14', 'MRI of Brain 14,15', 'X', 'X', 'X', 'X', 'X', 'Bone Scan 14,16', 'X', 'Subsequent Antineoplastic', 'X', 'X', 'X', 'X', 'Therapy Status', 'Survival Status5', 'Study Drug Administration', 'Pembrolizumab17', 'X', 'X', '1.', 'Procedures and assessments completed at the time of withdrawal from the main study may be used, as appropriate, for the start of the Second', 'Course', 'Phase', 'of', 'the', 'study.', 'Otherwise, assessments and procedures are to be performed on Day 1 and prior to the first dose of trial treatment for each cycle, unless specified.', '2.', 'The Discontinuation Visit should occur at the time study drug is discontinued for any reason. If the Discontinuation Visit occurs 30 days from the last dose of study', 'treatment (ie, at the time of the mandatory Safety Follow-up Visit), procedures required at both visits only need to be performed once.', '3.', 'The mandatory Safety Follow-up Visit for all subjects should be conducted approximately 30 days after the last dose of trial treatment or before the initiation of new', 'antineoplastic treatment, whichever comes first. Subjects with an AE of Grade >1 will be further followed until the resolution of the AE to Grade 0-1 or until beginning of a', 'new antineoplastic therapy, whichever occurs first. If the Discontinuation Visit occurs approximately 30 (3) days from last dose trial treatment the same procedures do not', 'need to be repeated for the Safety Follow-up Visit.', '4.', 'Subjects who discontinue from the treatment phase prior to disease progression will continue to be followed in PFS follow-up until they experience disease progression or', 'start a new antineoplastic therapy. Subjects with an AE of Grade >1 will be further followed until the resolution of the AE to Grade 0-1 or until beginning of a new', 'antineoplastic therapy, whichever occurs first.', '5.', 'Once the subject stops the imaging assessments for this protocol (eg, for PD or starting a new antineoplastic therapy), the subject moves into the Survival Follow-up and', \"should be contacted by telephone every 8 weeks to assess for survival status. Post-study treatments and the subject's response to them will also be collected. Updated\", 'survival status may be requested by the Sponsor at any time during the course of the study. Upon Sponsor notification, all participants who do not/will not have a scheduled', 'study visit or study contact during the Sponsor defined time period will be contacted for their survival status (excluding participants that have a death event previously', 'recorded).', '6.', 'In general, the window for each visit is +3 days unless otherwise noted. If treatment cycles are adjusted all procedures except imaging will be completed according to the', 'Cycle number and not weeks on treatment; imaging will not be adjusted for delays in treatment cycles and will be performed per calendar schedule. The visit windows for', 'follow-up are indicated in days.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}